1093625-98-9 Usage
Chloropyrimidine group
A chemical group derived from pyrimidine, a heterocyclic aromatic organic compound, with a chlorine atom attached to the 6th position. This group is part of the structure of 2-(6-Chloropyrimidin-4-yl)-2H-[1,2,4]triazol-3-ylamine and is of interest due to its potential biological activity.
Triazol-3-ylamine group
A chemical group consisting of a triazole ring (a five-membered ring with two nitrogen atoms and one oxygen atom) and an amine group (a nitrogen atom with two hydrogen atoms) attached to the 3rd position. This group is also part of the structure of 2-(6-Chloropyrimidin-4-yl)-2H-[1,2,4]triazol-3-ylamine and is of interest due to its potential biological activity.
Pharmaceutical and agricultural industries
2-(6-Chloropyrimidin-4-yl)-2H-[1,2,4]triazol-3-ylamine is of interest to researchers in these industries due to its potential use as a building block for the synthesis of a variety of biologically active molecules. This indicates the potential applications of 2-(6-Chloropyrimidin-4-yl)-2H-[1,2,4]triazol-3-ylamine in the development of new drugs and pesticides.
Anti-cancer and anti-inflammatory agent
2-(6-Chloropyrimidin-4-yl)-2H-[1,2,4]triazol-3-ylamine has been studied for its potential as an anti-cancer and anti-inflammatory agent. This indicates the potential therapeutic uses of 2-(6-Chloropyrimidin-4-yl)-2H-[1,2,4]triazol-3-ylamine.
Check Digit Verification of cas no
The CAS Registry Mumber 1093625-98-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,6,2 and 5 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1093625-98:
(9*1)+(8*0)+(7*9)+(6*3)+(5*6)+(4*2)+(3*5)+(2*9)+(1*8)=169
169 % 10 = 9
So 1093625-98-9 is a valid CAS Registry Number.
1093625-98-9Relevant articles and documents
PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF
-
Page/Page column 29, (2009/01/23)
The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, CSK, C-Src, EphB1, EphB2, EphB4, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα, SAPK2α, Src, SIK, Syk, Tie2 and TrkB kinases.
